Printed from Voxsanity (voxsanity.com.au) — NCT07173712 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Type 2 Diabetes
Phase 4 Type 2 Diabetes Trial, Not Yet Recruiting
NCT07173712
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with type 2 diabetes for more than 1 year but less than 15 years.
- People who have been taking at least one diabetes tablet at a stable dose for 3 months or longer.
- People whose blood sugar control (measured by a specific blood test called HbA1c) is above a certain level at the screening visit — above 8.0% if taking one diabetes tablet, or above 7.5% if taking more than one.
- People aged between 18 and 70 years old.
- People with a body mass index (a measure of height and weight) between 20 and 35.
- People who are able and willing to follow all study requirements, including wearing a continuous glucose monitor, checking their own blood sugar levels, making lifestyle changes, and following an insulin-based treatment plan.
- People who agree to use reliable contraception throughout the study.
- People who are willing to sign a written consent form agreeing to take part.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have type 1 diabetes or another specific type of diabetes (not type 2).
- People who have recently used certain insulin treatments or a GLP-1 medication (a type of injectable diabetes medicine) within the past several months, or who cannot tolerate the doses specified in the study plan (confirm with trial site for exact timeframes).
- People who have a known allergy or intolerance to the medications used in this study.
- People currently experiencing serious diabetes-related emergencies such as diabetic ketoacidosis or severely high blood sugar with dangerous complications.
- People with serious diabetes-related complications affecting the eyes, kidneys, or nerves, or serious heart or blood vessel problems such as a recent stroke, heart attack, unstable chest pain, uncontrolled irregular heartbeat, severe heart failure, or a recent procedure or amputation due to poor circulation in the legs.
- People with persistently very high blood pressure, specifically above 180/110 mmHg, or blood pressure that remains above 160/110 mmHg and is not controlled within the past week.
- People with significantly reduced kidney function, or liver enzyme or bilirubin levels that are notably above the normal range (confirm with trial site for exact values).
- People with a low haemoglobin level (below 100 g/L) or who need regular blood transfusions.
- People who have used certain medications that affect blood sugar levels in the 12 weeks before the screening visit for more than one week in total — including steroid tablets or injections, growth hormone, oestrogen or progesterone, high-dose water tablets, or antipsychotic medicines (some exceptions apply, such as low-dose water tablets for blood pressure or standard thyroid hormone replacement).
- People with a hormone disorder that is not well controlled.
- People with a personal or family history of a specific type of thyroid cancer (medullary thyroid carcinoma) or a condition called multiple endocrine neoplasia syndrome type 2.
- People with a psychiatric illness or a condition that makes communication difficult.
- People with an active widespread infection, a serious ongoing illness, cancer, or chronic diarrhoea.
- People who are pregnant, breastfeeding, or women who could become pregnant but are unwilling to use contraception during the study.
- People who are unlikely to attend follow-up visits or complete the study, as judged by the study investigators.
- People with any other condition considered unsuitable by the study investigators, including a history of acute pancreatitis, rapidly worsening gallstones, or long-term gallbladder inflammation.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Yanbing Li
Registry
ClinicalTrials.gov
Start date
15 March 2026
Est. completion
30 June 2027
Primary endpoints
Proportion of subjects with optimal glycemic control
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.